东亚药业：上半年归母净利润亏损3022.83万元

Core Viewpoint - East Asia Pharmaceutical reported a significant decline in revenue and incurred a net loss in the first half of the year, indicating potential challenges in its financial performance and market position [1] Financial Performance - The company achieved an operating revenue of 416 million yuan in the first half of the year, representing a year-on-year decrease of 35.85% [1] - The net profit attributable to shareholders was a loss of 30.2283 million yuan, with a basic earnings per share of -0.26 yuan per share [1]